<DOC>
	<DOCNO>NCT02918136</DOCNO>
	<brief_summary>This prospective , randomize , multi-site , safety efficacy study subject rotator cuff injury . Patients fall two category : treatment group ( 12 subject ) non-treatment control group ( six subject ) . The treatment group undergo small liposuction procedure receive rotator cuff repair treatment ultrasound-guided injection 5cc adipose-derived stem cell ( ADSCs ) point injury . The control group receive 5cc cortisone injection point injury</brief_summary>
	<brief_title>Safety Efficacy Adipose-Derived Stem Cell Injection Partial Thickness Rotator Cuff Tears</brief_title>
	<detailed_description />
	<mesh_term>Cortisone acetate</mesh_term>
	<mesh_term>Cortisone</mesh_term>
	<criteria>1 . Males females 3075 year age . 2 . Clinical symptom consistent rotator cuff lesion include limited pain , muscle weakness , activelimited range motion ( AROM ) . 3 . Subjects respond physical therapy treatment least six week . 4 . Subjects &gt; 70 % passive range motion ( PROM ) . 5 . Diagnosed &gt; 50 % tear supraspinatus muscle &lt; 5mm separation assess MRI . 6 . Diagnosed partialthickness rotator cuff tear 7 . The ability subject give appropriate consent appropriate representative available . 1 . Age &lt; 30 &gt; 75 2 . Insufficient amount subcutaneous tissue allow recovery 50cc lipoaspirate . 3 . History systemic malignant neoplasm within last 5 year . 4 . History local neoplasm within last 6 month history local neoplasm site administration . 5 . Subject receive immunosuppressant therapy know immunosuppressive severe autoimmune disease require chronic immunosuppressive therapy ( e.g. , human immunodeficiency virus , systemic lupus erythematosus , etc. ) . 6 . Subjects know HIV positive 7 . Patients receive corticosteroid injection rotator cuff site within last 3 month 8 . Severe arthrosis glenohumeral acromioclavicular joint 9 . Irreparable rotator cuff tear ( include rotator cuff tear arthropathy ) 10 . Fatty atrophy Grade 2 affect shoulder 11 . Previous shoulder surgery affect shoulder 12 . History tobacco use within last 3 month 13 . Any contraindication MRI scan accord MRI guideline , unwillingness undergo MRI procedures 14 . Patients active regimen chemotherapy 15 . Patients document history liver disease ALT value &gt; 400 16 . Allergy sodium citrate `` caine '' type local anesthetic 17 . Patients pregnant breast feed 18 . Subject opinion Investigator designee , unable comply requirement study protocol unsuitable study reason . This include completion Patient Reported Outcome instrument . 19 . Subject currently participate another clinical trial yet complete primary endpoint . 20 . Subject part vulnerable population , judgment investigator , unable give Informed Consent reason incapacity , immaturity , adverse personal circumstance lack autonomy . This may include : Individuals mental disability , person nurse home , child , impoverished person , person emergency situation , homeless person , nomad , refugee , incapable give informed consent . Vulnerable population also may include member group hierarchical structure university student , subordinate hospital laboratory personnel , employee Sponsor , member arm force , person keep detention . 21 . Uncooperative patient neurological/psychiatric disorder incapable follow direction predictably unwilling return followup examination .</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>